For high-risk patients, the method could offer a safer alternative to open-heart surgery.
In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.
BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback